AgingPhase 2ABLENCT05706389
Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?
A Phase 2 study testing Ca-AKG in people with Aging, run by National University of Singapore at 1 site in Singapore.
Trial summary
Geroscience is an emerging interdisciplinary field of study in gerontological sciences. With emphasis on understanding the mechanistic drivers of aging, it seeks translational approaches that could eventually be applied to improve human healthspan and delay age-associated chronic diseases. Read more about this study
- Who is it for?
- Ages 40 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Aging
- What is being tested?
- Ca-AKG
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteSingapore
- Study dates
- 24 Feb 2023to 15 Jan 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- participants whose biological age (as measured by blood DNA methylation) is greater than their chronological age
Who cannot join
- pregnant women
- more than ONE of the following chronic medical conditions (based on the medical history and during screening), they are NOT eligible to participate in the study:
- Waist circumference more than or equal to 90 cm for males or more than or equal to 80 cm for females
- Fasting triglycerides more than or equal to 1.7 mmol/l
- High-density lipoprotein less than 1.0 mmol/l in men or less than 1.3 mmol/l in women
- Blood pressure more than or equal to 130/85 mmHg or use of antihypertensive medication
Show all 26Show fewer
- Fasting glucose more than or equal to 6.0 mmol/l
- Osteopenia
- Mild Osteoarthritis not interfering in daily activities
- Fatty liver
- Participants will NOT be recruited if they fall in the following categories:
- Pre-existing, or history of major CVD (coronary artery disease, heart failure, stroke, peripheral vascular disease, pulmonary hypertension), severe/uncontrolled hypertension (under 3 or more than 3 prescribed medications), rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism
- Type 1 diabetes and Type 2 diabetes under oral metformin or insulin therapy and with diabetic complications such as diabetic retinopathy, diabetic nephropathy
- Active cancer or treatment of cancer in the last 3 years
- Chronic obstructive pulmonary disease (COPD), severe asthma (taking daily medications)
- Pregnant women will not be recruited into this study because of the safety issues associated with X-ray irradiation during DXA scan
- Potential female participants who plan on pregnancy within the next 9 months of study period
- Multiple sclerosis and autoimmune/immune deficiency diseases such as Rheumatic arthritis, HIV, Crohn's disease
- Recent history of sepsis or infection (within 3 months of in-patient hospitalization)
- Any psychiatric disease or neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Lewy body dementia, and any eating disorders
- Any metal implants in the body
- Hepatitis and Liver cirrhosis (independent of severity)
- Severe kidney disease (GFR less than 30 ml/min/1.73 m2)
- Skin disease (on oral or systemic medication for immune system)
- Subjects receiving any other similar investigational product within 60 days or 5 halflives before the screening, whichever that is longer
- Any serious medical illness which in the PI's judgment may jeopardize the subject by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study
Trial locations and contacts
1 site in 1 country.
Singapore1 site
Centre for Healthy Longevity, Alexandra Hospital
Singapore, 159964
About this study
Geroscience is an emerging interdisciplinary field of study in gerontological sciences. With emphasis on understanding the mechanistic drivers of aging, it seeks translational approaches that could eventually be applied to improve human healthspan and delay age-associated chronic diseases. Contrary to popular opinion that aging is irreversible, advances in geroscience research have demonstrated that aging is modifiable and inhibiting or activating specific molecular pathways can improve healthspan and extend lifespan in model organisms. Advocates of geroscience take the view that age-related chronic diseases are best treated by slowing the aging process, rather than using the prevailing disease-centric approach of addressing each disease alone. Thus, the concept is that biological aging, rather than chronological aging, is amenable to intervention.
In this regard, geroscientists are at the forefront of longevity medicine in rigorously testing novel supplements, drugs and other prophylactics that can enhance healthspan. Some of these interventions involve repurposing existing drugs such as rapamycin, a well-known immunosuppressant, at different dosing regimens to specifically target biological hallmarks of aging.
This study will investigate the effects of alpha-ketoglutarate (AKG), an endogenous metabolite, on biomarkers of aging in middle-aged residents of Singapore.
Read the detailed description
Recent growing understanding on mechanisms of aging as gradual changes in body systems through several cellular and molecular levels has raised research interests in the biology of aging. There are seven established overlapping processes of aging: oxidative stress, macromolecular damage, epigenetic changes, abnormal metabolism, impaired proteostasis, decline in stem cell functions and inflammation. These overlapping changes over the lifetime affect the onset of age-related diseases and possibly the aging process itself. However, lifestyle and pharmacologic interventions can modify the deterioration of aging pathways. AKG is a generally regarded as safe (GRAS) micronutrient and has shown great potential in extending healthspan. Here, we aim to study the role of AKG in the modulation of aging.
The aim is to evaluate the anti-aging function of AKG and determine whether AKG can modulate biological pathways of aging in middle-aged adults in Singapore. Our hypothesis is that AKG will affect DNA methylation which will be associated with the change in blood biomarkers of aging and change in physiological function. It allows us to study the longitudinal effects of AKG on clinical and biological outcomes.
This is a 6-month double-blinded, placebo-controlled longitudinal interventional study on middle-aged participants to study the effect of AKG on biomarkers of aging, with another 3 months of post-intervention follow-up. The total duration of participation in this study is 9 months.
The rationale for this study design is to study the long-term effect of 1 g AKG in middle-aged adults. Our study design of 6 months of intervention (1 g AKG vs placebo) will allow us to understand the effect of AKG treatment on DNA methylation, and another 3 months of post-intervention follow-up will help us understand if there is any long-term effect of AKG. In order to minimize recruitment bias, our study design is double-blinded.
- Conditions
- Aging
- Being tested
- Ca-AKG
- Keywords
- Aging, Geroscience, Alpha-Ketoglutarate, DNA methylation, Healthspan, epigenetic aging clock
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ca-AKGDietary supplement
Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
| Study group | Role | What they receive |
|---|---|---|
| Ca-AKG | Experimental | Pill format, 500mg/pill, half of daily dose Receives: Dietary Supplement: Ca-AKG |
| Placebo | Placebo comparator | Pill format, indistinguishable from active pill Receives: Dietary Supplement: Ca-AKG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in blood DNA methylation status, years
DNA methylation aging clock
Measured: from baseline to end of intervention (6 months)
Secondary outcomes (34)
Complete blood count
comparison of blood count at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Carotid-femoral Pulse Wave Velocity change
comparison of PWV at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Central Blood pressure change
comparison of Central Blood pressure at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Body Mass Index (BMI) change
comparison of BMI at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Brachial Blood pressure change
comparison of Brachial Blood pressure at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Waist/hip ratio change
comparison of Waist/hip ratio at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Bone Mineral Density, g/cm2 change
comparison of Bone Mineral Density at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Fat-free mass, change (kg)
comparison of fat-free mass at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Fat mass, change (kg)
comparison of fat mass at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Handgrip strength change (kg)
comparison of handgrip strength at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
8-RM leg extension change (kg)
comparison of 8RM leg extension at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption (V̇O2), L/min
comparison of VO2 during CPET at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption per kg body weight (V̇O2/kg), L/min/kg
comparison of VO2/kg during CPET at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): change in lactate
comparison of lactate levels during CPET at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): change in heart rate
comparison of heart rate levels during CPET at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): aerobic and anaerobic threshold change
comparison of aerobic and anaerobic threshold levels during CPET at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): excess post-exercise oxygen consumption change
comparison of excess post-exercise oxygen consumption levels during CPET at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Change in Skin autofluorescence, au
comparison of skin autofluorescence levels at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Change in Quality-of-Life questionnaires (SF-36 questionnaires)
comparison of Quality-of-life at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Change in Quality-of-Life questionnaires (EuroQoL-5D-5L)
comparison of Quality-of-life at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Change in Sleep (modified Pittsburgh sleep quality Questionnaire )
comparison of sleep at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Change in Sleep (Satisfaction, Alertness, Timing, Efficiency and Duration (SATED) Questionnaire )
comparison of sleep at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
Change in Global preferences survey (GPS)
comparison of global preferences (GPS) at baseline and 6 months
Measured: from baseline to end of intervention (6 months)
AKG, glutamate, glutamine concentrations in serum
Metabolites in serum change
Measured: from baseline to end of intervention (6 months)
Change in Immune parameters (Complete Blood Count)
Immune parameters change
Measured: from baseline to end of intervention (6 months)
Change in Immune parameters (inflammatory parameters in serum, mg/dL)
Immune parameters change
Measured: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Renal function, mg/dL
Clinical Blood parameters change
Measured: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Lipid profile test, mmol/L
Clinical Blood parameters change
Measured: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Glucose, mg/dL
Clinical Blood parameters change
Measured: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: insulin, mg/dL
Clinical Blood parameters change
Measured: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: HbA1C, mmol/mol
Clinical Blood parameters change
Measured: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Metabolites, mmol/l
Clinical Blood parameters change
Measured: from baseline to end of intervention (6 months)
Change in Cognitive function test by Montreal Cognitive Assessment (MoCA)
Cognitive function change
Measured: from baseline to end of intervention (6 months)
Change in saliva DNA methylation status, years
DNA methylation aging clock
Measured: from baseline to end of intervention (6 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2023
- Study start24 Feb 2023
- Primary completion15 Aug 2025
- Study completion15 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AgingStudies of the same condition, open and under way.
- More trials run by National University of SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double-blinded, placebo-controlled longitudinal interventional study on middle-aged participants
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University of Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- AMILI Pte. Ltd., Genome Institute of Singapore
- Responsible party
- Principal investigator, Andrea Maier, National University of Singapore
- Investigators
- Andrea B Maier, MD, PhD, Principal investigator, National University of Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05706389
- Sponsor's protocol ID
- NUS-IRB-2021-946
- Acronym
- ABLE
- Status last verified
- May 2026
- First submitted
- 25 Dec 2022
- Last updated
- 26 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lu JK, Wang W, Chew YE, Guan L, Kennedy BK, Maier AB. Optimizing accelerometer implementation in a gerotherapeutic trial: Feasibility, adherence, and operational insights of ABLE. PLOS Digit Health. 2026 Sep 25;5(9):e0001691. doi: 10.1371/journal.pdig.0001691. eCollection 2026 Sep.
PubMed 42789532
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?
- ClinicalTrials.gov ID
- NCT05706389
- Acronym / sponsor ID
- ABLE / NUS-IRB-2021-946
- Conditions
- Aging
- Keywords
- Aging, Geroscience, Alpha-Ketoglutarate, DNA methylation, Healthspan, epigenetic aging clock
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- National University of SingaporeUniversity, hospital or other
- Collaborators
- AMILI Pte. Ltd., Genome Institute of Singapore
- Study start
- 24 Feb 2023 (actual)
- Primary completion
- 15 Aug 2025 (actual)
- Study completion
- 15 Jan 2027 (estimated)
- First posted
- 31 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Geroscience is an emerging interdisciplinary field of study in gerontological sciences. With emphasis on understanding the mechanistic drivers of aging, it seeks translational approaches that could eventually be applied to improve human healthspan and delay age-associated chronic diseases. Contrary to popular opinion that aging is irreversible, advances in geroscience research have demonstrated that aging is modifiable and inhibiting or activating specific molecular pathways can improve healthspan and extend lifespan in model organisms. Advocates of geroscience take the view that age-related chronic diseases are best treated by slowing the aging process, rather than using the prevailing disease-centric approach of addressing each disease alone. Thus, the concept is that biological aging, rather than chronological aging, is amenable to intervention.
In this regard, geroscientists are at the forefront of longevity medicine in rigorously testing novel supplements, drugs and other prophylactics that can enhance healthspan. Some of these interventions involve repurposing existing drugs such as rapamycin, a well-known immunosuppressant, at different dosing regimens to specifically target biological hallmarks of aging.
This study will investigate the effects of alpha-ketoglutarate (AKG), an endogenous metabolite, on biomarkers of aging in middle-aged residents of Singapore.
Detailed description
Recent growing understanding on mechanisms of aging as gradual changes in body systems through several cellular and molecular levels has raised research interests in the biology of aging. There are seven established overlapping processes of aging: oxidative stress, macromolecular damage, epigenetic changes, abnormal metabolism, impaired proteostasis, decline in stem cell functions and inflammation. These overlapping changes over the lifetime affect the onset of age-related diseases and possibly the aging process itself. However, lifestyle and pharmacologic interventions can modify the deterioration of aging pathways. AKG is a generally regarded as safe (GRAS) micronutrient and has shown great potential in extending healthspan. Here, we aim to study the role of AKG in the modulation of aging.
The aim is to evaluate the anti-aging function of AKG and determine whether AKG can modulate biological pathways of aging in middle-aged adults in Singapore. Our hypothesis is that AKG will affect DNA methylation which will be associated with the change in blood biomarkers of aging and change in physiological function. It allows us to study the longitudinal effects of AKG on clinical and biological outcomes.
This is a 6-month double-blinded, placebo-controlled longitudinal interventional study on middle-aged participants to study the effect of AKG on biomarkers of aging, with another 3 months of post-intervention follow-up. The total duration of participation in this study is 9 months.
The rationale for this study design is to study the long-term effect of 1 g AKG in middle-aged adults. Our study design of 6 months of intervention (1 g AKG vs placebo) will allow us to understand the effect of AKG treatment on DNA methylation, and another 3 months of post-intervention follow-up will help us understand if there is any long-term effect of AKG. In order to minimize recruitment bias, our study design is double-blinded.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double-blinded, placebo-controlled longitudinal interventional study on middle-aged participants
| Arm | Type | Receives |
|---|---|---|
| Ca-AKG | Experimental | Dietary Supplement: Ca-AKGPill format, 500mg/pill, half of daily dose |
| Placebo | Placebo comparator | Dietary Supplement: Ca-AKGPill format, indistinguishable from active pill |
Who may qualify
- Ages
- 40 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- participants whose biological age (as measured by blood DNA methylation) is greater than their chronological age
Key exclusion criteria (26 listed)
- pregnant women
- more than ONE of the following chronic medical conditions (based on the medical history and during screening), they are NOT eligible to participate in the study:
- Participants will NOT be recruited if they fall in the following categories:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ca-AKGEligible participants will be randomised to receive Ca-AKG or Placebo for 6 months. | Dietary supplement | Ca-AKG, Placebo |
Primary outcome
Change in blood DNA methylation status, years
Time frame: from baseline to end of intervention (6 months)
DNA methylation aging clock
34 secondary outcomes
Complete blood count
Time frame: from baseline to end of intervention (6 months)
Carotid-femoral Pulse Wave Velocity change
Time frame: from baseline to end of intervention (6 months)
Central Blood pressure change
Time frame: from baseline to end of intervention (6 months)
Body Mass Index (BMI) change
Time frame: from baseline to end of intervention (6 months)
Brachial Blood pressure change
Time frame: from baseline to end of intervention (6 months)
Waist/hip ratio change
Time frame: from baseline to end of intervention (6 months)
Bone Mineral Density, g/cm2 change
Time frame: from baseline to end of intervention (6 months)
Fat-free mass, change (kg)
Time frame: from baseline to end of intervention (6 months)
Fat mass, change (kg)
Time frame: from baseline to end of intervention (6 months)
Handgrip strength change (kg)
Time frame: from baseline to end of intervention (6 months)
8-RM leg extension change (kg)
Time frame: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption (V̇O2), L/min
Time frame: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption per kg body weight (V̇O2/kg), L/min/kg
Time frame: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): change in lactate
Time frame: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): change in heart rate
Time frame: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): aerobic and anaerobic threshold change
Time frame: from baseline to end of intervention (6 months)
Cardiopulmonary exercise test (CPET): excess post-exercise oxygen consumption change
Time frame: from baseline to end of intervention (6 months)
Change in Skin autofluorescence, au
Time frame: from baseline to end of intervention (6 months)
Change in Quality-of-Life questionnaires (SF-36 questionnaires)
Time frame: from baseline to end of intervention (6 months)
Change in Quality-of-Life questionnaires (EuroQoL-5D-5L)
Time frame: from baseline to end of intervention (6 months)
Change in Sleep (modified Pittsburgh sleep quality Questionnaire )
Time frame: from baseline to end of intervention (6 months)
Change in Sleep (Satisfaction, Alertness, Timing, Efficiency and Duration (SATED) Questionnaire )
Time frame: from baseline to end of intervention (6 months)
Change in Global preferences survey (GPS)
Time frame: from baseline to end of intervention (6 months)
AKG, glutamate, glutamine concentrations in serum
Time frame: from baseline to end of intervention (6 months)
Change in Immune parameters (Complete Blood Count)
Time frame: from baseline to end of intervention (6 months)
Change in Immune parameters (inflammatory parameters in serum, mg/dL)
Time frame: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Renal function, mg/dL
Time frame: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Lipid profile test, mmol/L
Time frame: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Glucose, mg/dL
Time frame: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: insulin, mg/dL
Time frame: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: HbA1C, mmol/mol
Time frame: from baseline to end of intervention (6 months)
Change in Clinical Blood parameters: Metabolites, mmol/l
Time frame: from baseline to end of intervention (6 months)
Change in Cognitive function test by Montreal Cognitive Assessment (MoCA)
Time frame: from baseline to end of intervention (6 months)
Change in saliva DNA methylation status, years
Time frame: from baseline to end of intervention (6 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
- Derived from this study: PubMed 42789532Lu JK, Wang W, Chew YE, Guan L, Kennedy BK, Maier AB. Optimizing accelerometer implementation in a gerotherapeutic trial: Feasibility, adherence, and operational insights of ABLE. PLOS Digit Health. 2026 Sep 25;5(9):e0001691. doi: 10.1371/journal.pdig.0001691. eCollection 2026 Sep.
- Individual participant dataSharing planned: No
Related trials for Aging
Recruiting
Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study
Aging, Dementia
Not yet recruitingObservational study
Prospective Research on Identification of Dementia in Early Stages (P.R.I.D.E)
Mild Cognitive Impairment, Memory Disorders
RecruitingObservational study
PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)
Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Plant-based Diet in Older People: What Consequences for Muscle Health?
Aging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrea B Maier, MD, PhD principal investigator
National University of Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Ca-AKG in people with Aging, run by National University of Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in blood DNA methylation status, years (time frame: from baseline to end of intervention (6 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05706389, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.